Enveda raises $311M at $2B valuation for nature-derived AI drugs
TechCrunch AI · rss · 2026-09-24
AI biotech Enveda has raised $311M at a $2 billion valuation to push more nature-derived AI-discovered drugs into clinical trials. Its pipeline includes treatments for skin conditions and drugs to preserve weight loss after stopping GLP-1s.
More from Venture
- Apple needed 7 years for market belief; today's market prices zero durability into the AI cycle — BenBajarin · 2026-11-11
- GPU Rental Prices Hit Record Highs: B200 at $6.97/hr, H100 at $3.06 — inductionheads · 2026-11-11
- UK chip start-up Fractile hits $7bn valuation, per FT — evisoft · 2026-11-11
- AMAT reports Thursday: DRAM hits 26% of tool sales, outlook is the real signal — tengyanAI · 2026-11-11
- Amazon's $ANT stake and notes could equal 13-16.5% of its own market cap — RihardJarc · 2026-11-11
- Anthropic reportedly guiding $140B revenue for 2027 and $280B for 2028 — zephyr_z9 · 2026-11-11